Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Johnson & Johnson (JNJ), Pfizer Inc. (PFE) and Merck & Co., Inc. (MRK): How the Dow (.DJI)’s Pharma Stocks Have Fared in 2013

The Dow Jones Industrial Average isn’t just for industrial stocks anymore. You can find all sorts of companies in the venerable average, with the Dow representing a nearly all-inclusive cross-section of the entire U.S. economy.

Pharma stocks aren’t a huge part of the Dow, with just two of its constituents focused solely on the space and a third reaping a substantial portion of its revenue from pharmaceuticals. Yet pharma stocks have made a big impression on investors because of their lucrative dividend yields. Let’s take a look at how these companies have fared so far in 2013 and what their prospects are for the rest of the year and beyond.

JNJ Total Return Price Chart

JNJ Total Return Price data by YCharts.

You may not think of Johnson & Johnson (NYSE:JNJ) as a pharmaceutical company, as it’s far better-known for its consumer products. But the health care conglomerate also produces proprietary drugs and medical devices, giving it a broad reach over the entire health care industry. Lately, even as the company has faced liability from recalls of its artificial hip replacements, Johnson & Johnson (NYSE:JNJ) has gotten help from its pharma division, as the approval of its type 2 diabetes drug Invokana represents a big step forward in diabetes treatment that could produce the company’s next blockbuster.

Meanwhile, pure pharma stocks Pfizer Inc. (NYSE:PFE) and Merck & Co., Inc. (NYSE:MRK) have both dealt with patent expirations of high-profile drugs over the past couple of years, including Merck & Co., Inc. (NYSE:MRK)’s Singulair and Pfizer Inc. (NYSE:PFE)’s Lipitor. Yet while revenue has predictably fallen since generic competition hit the market, both companies have held up better than pessimists had expected.

For Pfizer Inc. (NYSE:PFE), anticlotting drug Eliquis, which it co-developed with Bristol Myers Squibb Co. (NYSE:BMY), has the potential to generate billions in sales over the next decade, having several advantages over rival drugs designed to replace the existing warfarin treatment for atrial fibrillation. Merck still faces some patent-cliff problems, with Vytorin, Nasonex, and Zetia coming off patent over the next four years. But with the combination of existing diabetes drugs Januvia and Janumet and up-and-coming development-stage drugs like insomnia treatment suvorexant and osteoporosis drug odanacatib, Merck & Co., Inc. (NYSE:MRK) has good prospects looking forward.

Keep looking for healthy results
With the pharma industry having turned the patent-cliff corner, pharma stocks should continue contributing to the Dow’s overall success. Given the emphasis on dividend income, the big yields that Pfizer Inc. (NYSE:PFE) and Merck & Co., Inc. (NYSE:MRK) pay will likely remain big drawing points for years to come.

The article How the Dow’s Pharma Stocks Have Fared in 2013 originally appeared on Fool.com and is written by Dan Caplinger.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Loading Comments...